Resolve Medical

Resolve Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for patients with severe autoimmune diseases, particularly systemic lupus erythematosus (SLE) and Sjögren's syndrome. The company's lead candidate, RSLV-132, is a first-in-class recombinant nuclease fusion protein designed to degrade potentially pathogenic RNA-DNA complexes that drive inflammation. By targeting the underlying cause of interferon alpha production rather than the cytokine itself, Resolve aims to provide a more effective and safer treatment option for chronic autoimmune conditions. The company is headquartered in Seattle, Washington, and is led by an experienced management team with a track record in drug development.